1. Home
  2. OXY vs ARGX Comparison

OXY vs ARGX Comparison

Compare OXY & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Occidental Petroleum Corporation

OXY

Occidental Petroleum Corporation

N/A

Current Price

$61.42

Market Cap

54.3B

Sector

Energy

ML Signal

N/A

Logo argenx SE

ARGX

argenx SE

N/A

Current Price

$1,043.41

Market Cap

58.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OXY
ARGX
Founded
1920
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.3B
58.4B
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
OXY
ARGX
Price
$61.42
$1,043.41
Analyst Decision
Hold
Strong Buy
Analyst Count
21
19
Target Price
$57.71
$1,008.56
AVG Volume (30 Days)
7.9M
306.5K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
1.71%
N/A
EPS Growth
N/A
N/A
EPS
5.89
N/A
Revenue
$21,593,000,000.00
N/A
Revenue This Year
$14.12
$44.39
Revenue Next Year
N/A
$20.84
P/E Ratio
$10.44
$33.69
Revenue Growth
N/A
N/A
52 Week Low
$38.80
$661.85
52 Week High
$67.45
$1,039.08

Technical Indicators

Market Signals
Indicator
OXY
ARGX
Relative Strength Index (RSI) 67.63 73.92
Support Level $52.89 $830.58
Resistance Level $67.45 N/A
Average True Range (ATR) 1.24 27.24
MACD 0.39 21.08
Stochastic Oscillator 91.40 93.73

Price Performance

Historical Comparison
OXY
ARGX

About OXY Occidental Petroleum Corporation

Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2025, the company reported net proved reserves of 4.6 billion barrels of oil equivalent. Net production averaged 1.4 million barrels of oil equivalent per day in 2025 at a ratio of roughly 74% oil and natural gas liquids and 26% natural gas.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: